lassa
fever
viral
hemorrhagic
fever
caused
lassa
virus
commonly
transmitted
rodent
host
endemic
certain
area
west
africa
several
hundred
thousand
people
estimated
infected
year
disease
asymptomatic
mild
approximately
infected
patient
remaining
severe
multisystem
disease
estimated
overall
mortality
death
rate
particularly
high
woman
third
trimester
pregnancy
fetus
die
uterus
infected
pregnant
mother
common
complication
lassa
fever
deafness
various
degree
deafness
occur
approximately
case
many
case
hearing
loss
permanent
disease
severity
seem
affect
complication
deafness
may
develop
mild
well
severe
case
lassa
fever
remains
serious
challenge
public
health
west
africa
threatening
local
resident
rural
area
serve
particularly
medical
care
provider
ribavirin
antiviral
drug
used
successfully
lassa
fever
patient
need
given
early
readily
available
infected
area
given
ecology
rodent
host
condition
endemic
area
vaccine
mandatory
control
lassa
vaccine
initiative
suffered
lack
funding
past
bioterrorism
recent
importation
disease
united
state
europe
brought
new
resource
lassa
virus
science
early
attempt
develop
lassa
fever
vaccine
focused
killed
pathogen
caused
strong
humoral
response
failed
protect
nonhuman
primate
test
animal
subsequently
recombinant
vaccine
used
vaccinia
vector
carrying
different
combination
structural
lassa
protein
protected
nonhuman
primate
lethal
challenge
absence
strong
humoral
response
suggesting
cellular
response
important
protection
use
vaccinia
vector
human
problematic
especially
area
hiv
infection
individual
develop
serious
skin
several
alternative
vaccine
based
vector
well
harmless
vaccinia
one
development
thomas
geisbert
colleague
report
promising
result
vaccine
based
attenuated
recombinant
vesicular
stomatitis
virus
vector
expressing
lassa
viral
glycoprotein
single
intramuscular
vaccination
protected
four
vaccinated
cynomolgus
macaque
lethal
challenge
particular
lassa
strain
two
control
monkey
received
empty
vector
died
injection
dose
virus
encouraging
result
future
larger
study
need
ass
duration
protection
demonstrate
safety
vaccine
another
crucial
question
quickly
vaccinated
individual
acquire
protection
thus
whether
vaccine
would
suitable
creating
ring
vaccination
around
outbreak
zone
likely
early
application
promising
candidate
vaccine
addition
least
four
different
strain
lassa
virus
ideal
vaccine
provide
protection
across
strain
finally
conducting
trial
endemic
area
many
lack
political
stability
remains
serious
challenge